Avedro, Inc. Names Thomas E. Griffin as Chief Financial Officer
June 20, 2017 at 05:30 pm IST
Share
Avedro, Inc. announced that Thomas E. Griffin has joined the company as chief financial officer (CFO). Mr. Griffin has more than 25 years of executive management experience at emerging growth medical technology companies. He brings a track record of success, leading both early-stage and commercial companies throughout his career. Tom's financial acumen combined with his significant experience in the medical technology industry for both private and publicly held companies will be a tremendous asset to Avedro. Mr. Griffin has spent his entire career in financial operations at medical technology and biotechnology companies. For 10 years and during the company's initial public offering, Mr. Griffin served as CFO of Entellus Medical, Inc. before transitioning to vice president of finance in May 2016. Prior to this, Mr. Griffin served in a variety of executive level financial positions at several organizations, including Digital Gene Technologies, Inc., Centerpulse Spine-Tech, Inc. (now Zimmer Spine, Inc.), and CIMA Labs Inc. (now owned by Teva Pharmaceutical Industries Ltd.). He is a member of Helius Medical Technologies, Inc.'s board of directors, where he is chairperson of the audit committee.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a âsingle dose pharmaceutical,â sold primarily in conjunction with the Companyâs innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.